If you have been reading about peptide hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Discovery == Apelin is a peptide hormone that was identified in 1998 by Masahiko Fujino and his colleagues at Gunma University and Takeda Pharmaceutical Company. In 2013, a second peptide hormone named Elabela was found by Bruno Reversade to also act as an endogenous ligand to the APLNR.
In the early nineteenth century, it was still undecided which port would be chosen as the primary sea link along the route from London to Dublin: Porthdinllaen, on the Llŷn Peninsula, or Holyhead in Anglesey. In May 1806, the Porthdinlleyn Harbour Act 1806 (46 Geo. 3. c. xxxiv) approved new buildings in Porthdinllaen when it seemed that the town would be chosen. Porthdinllaen was almost as far west as Holyhead, but Holyhead was more accessible because of Thomas Telford's road developments. Porthdinllaen Harbour Company was formed in 1808 in preparation, but the bill before Parliament to constitute Porthdinllaen as a harbour for Irish trade was rejected in 1810. Holyhead's maritime importance was at its height in the 19th century with a 1+3⁄4-mile-long (2.8-kilometre) sea breakwater. Holyhead Breakwater, built to create a safe harbour for vessels caught in stormy waters on their way to Liverpool and the industrial ports of Lancashire; it is the longest breakwater in the UK. Throughout the later 18th century and the entire 19th century, Holyhead was a crucial transit point for landed gentry and British parliamentarians and military officials who were travelling from Ireland to London. It was also a transit point for British owners of multinational estates visiting their 'other lands' or London houses. The port of Holyhead saw significant development throughout the 19th century to accommodate the growing passenger traffic between Holyhead and Dublin, which reached approximately 14,000 passengers annually by 1814.
== Adverse effects == Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides. Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils. Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.
On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:
The properties of acids and bases are relevant to physical organic chemistry. Organic chemists are primarily concerned with Brønsted–Lowry acids/bases as proton donors/acceptors and Lewis acids/bases as electron acceptors/donors in organic reactions. Chemists use a series of factors developed from physical chemistry -- electronegativity/Induction, bond strengths, resonance, hybridization, aromaticity, and solvation—to predict relative acidities and basicities. The hard/soft acid/base principle is utilized to predict molecular interactions and reaction direction. In general, interactions between molecules of the same type are preferred. That is, hard acids will associate with hard bases, and soft acids with soft bases. The concept of hard acids and bases is often exploited in the synthesis of inorganic coordination complexes.
Sources: en.wikipedia.org
== Third island chain == The third island chain is the final part of the strategy. This island chain begins at the Aleutian Islands and runs south across the center of the Pacific Ocean towards Oceania, through the Hawaiian Islands, American Samoa, and Fiji, to reach New Zealand. Australia serves as the staple between the second and third chains.
== Mirin kasu nutrition == Mirin kasu contains water, alcohol, fat, carbohydrate, and protein. A type of protein called resistant protein can be found in Mirin kasu. Resistant protein is beneficial to the consumers' health because it can improve immunity against lifestyle-related diseases including tumorigenesis, gallstone formation, corpulence hypercholesterolemia, constipation, and improving enteric fermentation of short-chain fatty acids.
== Definition == The word Wagyu literally means "Japanese cattle" and does not denote a single breed. Before the modern breeds were established, Japan had regional populations of native cattle. After the Meiji Restoration in 1868, most were crossed for several generations with imported breeds, mainly British and continental European cattle. Two uncrossed native populations, the Mishima and Kuchinoshima cattle, survive and are considered to have remained free from European genetic influence. In modern Japanese breed and meat classifications, Wagyu usually means four breeds: the Japanese Black, Japanese Brown, Japanese Polled, and Japanese Shorthorn. Beginning in the late nineteenth century, these breeds developed from regional native cattle crossed with imported stock. The imported breeds used differed by breed and region. The resulting cattle were later established as distinct breeds through selection and closed breeding. After bovine spongiform encephalopathy (BSE) was first confirmed in Japan in 2001, the Beef Traceability Law was enacted in 2003. The system assigns each animal a ten-digit identification number and records its birth and movements; it applies to all cattle in Japan, not only Wagyu. This system is also used to verify the labeling requirements introduced for Wagyu beef in 2007. Under guidelines issued by the Ministry of Agriculture, Forestry and Fisheries, the designation Wagyu is recommended only for beef from cattle documented as one of the four breeds or specified crosses between them and confirmed as having been born and raised in Japan.
=== United States === The seaweed has been found in several harbors in southern California. In May 2009 it was discovered in San Francisco Bay and aggressive efforts are underway to remove it before it spreads.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.